 Home > Active Ingredient News > Blood System > Clin Cancer Res: 9-year follow-up results for patients with follicular lymphoma after receiving alloSCT or autoSCT

Clin Cancer Res: 9-year follow-up results for patients with follicular lymphoma after receiving alloSCT or autoSCT

 Last Update: 2021-08-26
 Source: Internet
 Author: User

Tags

small lymphocytic lymphoma

5 8 chain

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Follicular lymphoma (FL) accounts for 20-30% of non-Hodgkin's lymphoma cases
.

Although the effectiveness of treatment has continued to improve in the past few decades, most FL patients will experience disease relapse after initial remission after first-line treatment

Lymphoma stem cells

This study aimed to compare the prognosis of patients with recurrent FL who received non-myeloablative allogeneic hematopoietic stem cell transplantation (alloSCT) and autologous hematopoietic stem cell transplantation (autoSCT)
.

Enrolled 194 FL patients who underwent hematopoietic stem cell transplantation at MD Anderson Cancer Center, of which 98 received alloSCT and 96 received autoSCT
.

The type of transplant used is based on donor availability and medical insurance reimbursement guidelines

OS and PFS in patients with recurrent FL after receiving autoSCT or alloSCT

The median follow-up time of survivors in the alloSCT group was 108 months, and that of the autoSCT group was 102 months
.

The overall survival rate of the alloSCT group was significantly longer than that of the autoSCT group (62% vs 46%; p=0.

The overall survival rate of patients in the alloSCT group was significantly longer than that of the autoSCT group.

Cumulative recurrence rate

In the alloSCT group, the incidence of grade 2-4 acute graft-versus-host disease (GVHD), grade 3-4 acute GVHD, and chronic GVHD were 22%, 9%, and 38%, respectively
.

In the autoSCT group, the 8-year incidence of secondary myelodysplasia was 11%

In short, the study showed that compared with autoSCT, alloSCT is curative and can provide a higher survival rate for patients with recurrent follicular lymphoma

For patients with recurrent follicular lymphoma, compared with autoSCT, alloSCT is curative and can provide a higher survival rate.

Original source:

Issa F.

9-year follow-up of patients with relapsed follicular lymphoma after nonmyeloablative allogeneic stem cell transplant and autologous transplant in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gadusol Powder Gadusol76663-30-4

CAS No.: 76663-30-4

Industrial Grade

$1-1.01/G FOB

Food Additive Iron fumarate for Nutritional Iron Supplements

CAS No.: 141-01-5

Pharmacy Grade

$24-26/G FOB

Aminobenzoic Acid CAS 56-91-7

CAS No.: 56-91-7

Pharmaceutical Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.